Investing.com - Gracell Biotechnologies reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Gracell Biotechnologies announced earnings per share of $-0.07 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.13 on revenue of $33.33K.
Gracell Biotechnologies shares are down 67% from the beginning of the year, still down 66.19% from its 52 week high of $11.80 set on November 23, 2021.
Gracell Biotechnologies shares gained 5.84% in intra-day trade following the report.
Gracell Biotechnologies follows other major Healthcare sector earnings this month
Gracell Biotechnologies's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar